Study Groups

The Bavarian Cancer Research Center (BZKF) offers fast and uncomplicated access to scientifically sound information and the latest therapy options. The promotion of clinical study groups for implementation in the quality of care is part of this.

Cross-site clinical study groups take over the implementation of clinical studies, with a focus on the rapid integration of new knowledge into everyday care. 

 The BZKF Study Groups:

• Acute myeloid leukemia (AML)
• Cancer of unknown primary (CUP)
• Colorectal cancer
• Head and neck tumor
• Lung tumor
• Lymphoma
• Malignant melanoma
• Breast cancer
• Multiple myeloma
• Pancreatic cancer
• Primary and secondary malignant brain tumors
• CNS tumors in children and adolescents

The following study groups were established in the fall of 2021 and are currently in the process of being established:

• Liver tumor
• Stomach and upper GI-tract
• Kidney cancer
• Ovarian cancer
• Prostate cancer
• R/R ALL
• Sarcomas
• Urothelial or transitionall-cell cancer

 Tasks

Cross-site clinical study groups take over the implementation of clinical studies, with a focus on the rapid integration of new knowledge into everyday care. In terms of content, the clinical study groups apply the following measures and instruments:

• Rapid and effective testing of innovative, translational approaches from the research laboratories and development departments of the University Hospitals for the prevention, diagnosis and treatment of cancers with a focus on networked pilot studies (Phase-I/II).
• Validation of promising approaches from Phase I/II study concepts in targeted Phase III Medicines Act (AMG) or Medical Devices Act (MPG) studies also in cooperation with local industrial partners.
• Networked patient-related research with the aim of reviewing and further developing research hypotheses, especially in the development of biomarkers or other predictive features.
• Epidemiological review of the efficacy and tolerability of new measures for early detection, prophylaxis, diagnosis and treatment of cancers.
• Investigation of the quality of life of patients with cancer with a focus on networked “outcome” studies using epidemiological data.
• Rapid integration of new knowledge into everyday care after a positive assessment by the networked “outcome” studies.

With this structure, the BZKF thus closes the gap between the findings of basic research and the resulting improvement in the established health care of cancer patients. The Bavarian Centre for Cancer Research forms the basis for effective patient-related cancer research and the clinical implementation of innovative treatment concepts developed in Bavaria in compliance with the Medicines Act (AMG) and medical devices act (MPG).

Study Participation:

Do you have any questions about studies or participation?
You can use the free PublicCancerHotline 0800 85 100 80. Our staff will be happy to help you!